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The matrix protein 2 (M2) blocker, Amantadin, is
approved by FDA to treat and control of influenza A
virus infections in children and adults. Recently, some
substitutions at amino acid positions are causing the
emergence of anti viral drug-resistant strains of influ-
enza virus.
To investigate the frequency of Amantadin resistance
among influenza A viruses isolated in children (up to 10
years old) referring to Children Infectious Research Cen-
ter in Tehran – Iran during the 2008 – 2009 Flu season,
124 samples were collected. Forty cases from them were
detected as influenza A virus by Reverse transcriptase
polymerase chain reaction (RT-PCR). The Large subunit
of hemagglutinin (HA1) and M2 genes were amplified
by RT-PCR followed by sequencing.
62.5% of positive cases were 0-3 years, 10% of them
were 4-6 years, and 27.5% were 7- 10 years. The result
shows 70% were male. 50% of positive cases affected
sporadic. Clinical symptoms in these positive cases were
as follows: Sudden onset 51%, fever 69.4%, headache
21.8%, coryza 82.5%, weakness 54.8%, pharingitis 41.1%,
bronchodyspenia 4%, cough 11.3%, agitation 58%, spu-
tum 59.7%, and muscle pain 8%, gastrointestinal pro-
blem, 23.4%, otitis 13%. 97.5% of these forty cases did
not received influenza vaccine and 40% received
antibiotic.
Our data show that Amantadin resistant A/H3 N2 is
caused by a single amino acid mutation that makes a
Ser 31 Asp substitution in M2 protein. Since these chil-
dren might not used Amantadin, the drug resistance
determined in this project is not related to direct usage
of Amantadin by the patient. Continued surveillance is
required to elucidate full Amantadin-resistant pattern of
influenza virus in Iranian children, especially in the
recent pandemics.
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